An engineered probiotic designed to treat a metabolic disease enters clinical trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
Microbiome Open Access 26 May 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Isabella, V. et al. Nat. Biotechnol. 36, 857–864 (2018).
Bermúdez-Humarán, L.G. et al. J. Immunol. 175, 7297–7302 (2005).
Lagenaur, L.A. et al. Mucosal Immunol. 4, 648–657 (2011).
Duan, F.F., Liu, J.H. & March, J.C. Diabetes 64, 1794–1803 (2015).
Durrer, K.E., Allen, M.S. & Hunt von Herbing, I. PLoS One 12, e0176286 (2017).
Whelan, R.A. et al. Mol. Ther. 22, 1730–1740 (2014).
Chen, Z. et al. J. Clin. Invest. 124, 3391–3406 (2014).
Plovier, H. et al. Nat. Med. 23, 107–113 (2017).
Quévrain, E. et al. Gut 65, 415–425 (2016).
Hamady, Z.Z. et al. Inflamm. Bowel Dis. 17, 1925–1935 (2011).
Limaye, S.A. et al. Cancer 119, 4268–4276 (2013).
Motta, J.P. et al. Sci. Transl. Med. 4, 158ra144 (2012).
Bermúdez-Humarán, L.G. et al. Microb. Cell Fact. 14, 26 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bermúdez-Humarán, L., Langella, P. Live bacterial biotherapeutics in the clinic. Nat Biotechnol 36, 816–818 (2018). https://doi.org/10.1038/nbt.4248
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4248